Quinton Oswold, President and CEO of Neurotech Pharmaceuticals Inc., sees huge opportunity both in wet AMD and diabetic macular edema patients who need more extensive and longer lasting therapies. Neurotech’s Encapsulated Cell Technology (ECT) platform provides long-term continuous delivery (2+years) of protein drugs directly into the vitreous of the eye. The company is developing multiple configurations of ECT for more customized delivery, and is about to enter Phase II studies of a single intravitreal implantation of its lead ECT candidate, NT-503, versus Eylea, to preserve vision in patients with recurrent or persistent wet AMD.
Quinton Oswald is the CEO of Neurotech. Prior to joining Neurotech, he served as the CEO of SARcode Bioscience, a San Francisco-based biotech that developed lifitegrast, an investigational product for dry eye disease.